Our Take
The industry's quality crisis is not a shortage of rules; it is a failure to distinguish what matters from what merely looks controlled, and regulators are now algorithmically identifying the paper-based systems that will fail first.
Why it matters
FDA inspections hit a 27% year-over-year spike in FY2024 and warning letters jumped 73% in H1 FY2025, while an internal AI system now flags high-risk facilities based on 483 histories and adverse events. Sponsors and CDMOs operating on compliance theater rather than genuine risk discipline are increasingly visible targets.
Do this week
Quality leads: audit your regulatory filings for over-specification that locks you into early-phase process choices, then document which QA functions must stay in-house (batch release, deviation management, change control) and which can move to specialist vendors before your next FDA inspection cycle.
Biopharma quality is declining under financial pressure, and regulators are escalating
Cytiva's 2025 Global Biopharma Index surveyed 1,250 senior biopharma executives across 22 countries in October 2025. The findings are stark: 40% believe cost-cutting is actively compromising product quality at their organizations, and 36% report that process changes are driven more by financial pressure than quality rationale (per Cytiva's survey). The overall industry resilience score fell to 5.96 out of 10 in 2025, down from 6.08 in 2023 and 6.60 in 2021.
The regulatory response has been direct and algorithmic. FDA conducted 989 drug inspections in FY2024, a 27% year-over-year increase, issuing 561 Form 483s to drug program firms (per FDA's FY2024 quality report). Over 62% of inspections targeted foreign manufacturing sites, the highest foreign-inspection share on record. In the first half of FY2025 alone, warning letters increased 73% compared to the same period in FY2024. In June 2025, the FDA launched an internal AI system called Elsa that analyzes 483 observation histories, adverse events, and CAPA records to prioritize high-risk facilities for inspection algorithmically.
This acceleration reflects a deeper structural problem: organizations are choosing between two failed strategies. Some over-build bureaucratic quality systems that consume resources without improving patient safety. Others cut costs without a framework, responding to financial pressure rather than quality logic. Both approaches substitute the appearance of rigor for its substance.
Risk-based quality management is not a compliance shortcut; it is the only approach that survives algorithmic inspection
The zero-risk mentality that has dominated biopharmaceutical manufacturing for decades creates what consulting leaders call "empire building." Organizations design quality systems so complex that only their architects can navigate them, locking in procedural details at Phase 1 that require costly regulatory amendments at Phase 3. Young sponsors, anxious to demonstrate rigor, over-describe their manufacturing processes in filings. This perceived thoroughness becomes an operational straitjacket once the process scales.
A risk-based framework asks three foundational questions for every quality activity: What is the return on doing this now? What is the patient and regulatory risk at this stage of the process? And what is the worst outcome if it is not done at this time? This approach focuses resources on issues that genuinely matter to product quality and patient safety, resisting the pull toward perfecting things with minimal impact.
The specific structure matters. Core QA functions—batch release, deviation management, change control—must remain internal to the manufacturing site because they require real-time operational information and site-specific institutional knowledge. Document control similarly demands on-site availability. At the same time, supplier audits can be efficiently handled by qualified consultants, and complex characterization and final release testing can often be delegated to specialist contract testing laboratories. The critical caveat is time: without robust service-level agreements that specify turnaround commitments and escalation pathways, outsourced testing becomes a scheduling liability.
The one-stop-shop CDMO model that evolved in the 2000s and 2010s is undergoing quiet reassessment. The true cost of full-service QC—hidden in rework, out-of-specification investigations, write-ups, and audits, plus the burden of retaining specialized laboratory staff—often exceeds the visible revenue. A CDMO with excellent manufacturing execution and strong in-process control, paired with a carefully selected external testing partner, may ultimately serve a program better than a facility trying to do everything under one roof.
Distinguish what regulators actually inspect from what compliance theater protects
Form 483 observations are widely treated as harbingers of catastrophe. They should not be. The FDA reviews operations across a broad spectrum of the industry, from leading-edge facilities to organizations running on decades-old systems. A 483 represents the agency's informed perspective on where a quality system can improve. Organizations that engage constructively with genuine corrective action, rather than defensive minimization, consistently modernize systems that had genuinely become liabilities.
The broader sponsor-CDMO-agency relationship succeeds when companies treat regulators as partners, not adversaries. Regulatory agencies share the fundamental goal of ensuring safe and effective products reach patients. Early and transparent engagement, bringing regulators into development thinking rather than presenting finished filings, consistently yields better outcomes than treating regulatory strategy as damage control.
The human dimension is too often an afterthought in quality system design. Manufacturing is behaviorally driven. Operators must follow sequences, attach connections, and make judgment calls under time pressure. A quality system that piles procedures on top of procedures without asking whether they are operationally feasible will fail through accumulated weight, not through documentation gaps. The most effective quality cultures treat manufacturing teams as partners in quality, training them to understand why procedures exist, not just how to follow them, and building feedback mechanisms that surface operational friction before it becomes a compliance problem. The real objective is conformance to requirements, with criticality placed where it belongs: on the things that protect patients and product integrity.